Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Sierra

‘Video games open us to the whole spectrum of human emotions’: novelist Gabrielle Zevin on Tomorrow, and Tomorrow, and Tomorrow

The writer who learned her craft playing 90s adventure games on her love letter to a lifelong passion, the problematic aspects of the industry and the transformative power of play

The Guardian - UK

'I've got a reputation to protect': How a game design legend was lured out of retirement

One of the most revered American game designers is sitting in the lower level of a yacht somewhere off the coast of Canada, discussing how she was unexpectedly dragged back into the life she left behind. Roberta Williams, creator of the franchise "King's Quest," a breakthrough in interactive storytelling and…

Los Angeles Times

Woman sparks debate after revealing that her friends didn’t know about her wedding until she sent invitations

‘I would feel so sad if my close friend did this,’ one viewer on TikTok wrote.

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Classic game fakes and forgeries – the great Ultima swindle

A recent game forgery scandal is hurting trust among collectors.

USA Today Sports Media Group

How to pack for your first multi-day hike for about $250

Hiking can be an expensive hobby, and we’re constantly bombarded by gear that's ultralight, and ultra-efficient. Here’s how to go on an adventure on a budget.

Input

GSK buys US-based cancer specialist Sierra Oncology for $1.9 billion

Deal is in step with GSK’s strategy of building a strong portfolio of new specialty medicines and vaccines

Evening Standard

GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal

GlaxoSmithKline plc (NYSE:GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ:SRRA) for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion). Sierra's momelotinib complements GSK's Blenrep (belantamab mafodotin), building on GSK's commercial and medical expertise in hematology. If momelotinib is approved, GSK expects momelotinib will contribute to GSK's growing…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Sierra Oncology's Bet On A Failed Gilead Drug Just Paid Off In A Big Way

Sierra Oncology reported a late-stage win Tuesday for a bone cancer drug it acquired at a discount — and the biotech stock catapulted.

Investors Business Daily

Sierra Oncology Secures Debt Facility Of Up To $125M With Oxford Finance To Support Momelotinib Development

Sierra Oncology Inc (NASDAQ: SRRA) has

Benzinga

Sierra Oncology Shares Rally As Bone Marrow Cancer Candidate Hits Primary Goal

Sierra Oncology Inc (NASDAQ: SRRA)

Benzinga

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.